## Filipa Farinha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3121911/publications.pdf

Version: 2024-02-01

		1477746	1372195
20	105	6	10
papers	citations	h-index	g-index
0.1	0.1	0.1	2.45
21	21	21	145
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Concerns of patients with systemic lupus erythematosus and adherence to therapy & mp; ndash; a qualitative study. Patient Preference and Adherence, 2017, Volume 11, 1213-1219.	0.8	28
2	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1446-1458.	1.1	26
3	Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology, 2021, 60, 1814-1822.	0.9	11
4	Impact of pegloticase on patient outcomes in refractory gout: current perspectives. Open Access Rheumatology: Research and Reviews, 2018, Volume 10, 141-149.	0.8	9
5	Outcomes of membranous and proliferative lupus nephritis – analysis of a single-centre cohort with more than 30 years of follow-up. Rheumatology, 2020, 59, 3314-3323.	0.9	9
6	Fracture risk in systemic lupus erythematosus patients over 28 years. Rheumatology, 2021, 60, 2765-2772.	0.9	7
7	Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up. Rheumatology, 2022, 62, 200-208.	0.9	4
8	Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus. Rheumatology, 2022, 62, 225-233.	0.9	4
9	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 4185-4198.	0.9	3
10	Major determinants of prolonged remission in systemic lupus erythematosus: retrospective study over a 41+ year period. Rheumatology, 2022, 62, 209-216.	0.9	2
11	E088 Antiphospholipase A2 receptor antibodies, a marker of idiopathic membranous nephropathy, are not present in membranous lupus nephritis. Rheumatology, 2019, 58, .	0.9	0
12	P170â€fPredictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. Rheumatology, 2020, 59, .	0.9	0
13	P172 Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. Rheumatology, 2020, 59, .	0.9	0
14	P59â€Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. , 2020, , .		0
15	P146â€Fracture risk in systemic lupus erythematosus patients over 25 years. , 2020, , .		0
16	P21â€Investigation of possible pathogenic autoantibodies in membranous lupus nephritis. , 2020, , .		0
17	P31â€Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. , 2020, , .		0
18	P42 Disease activity, impaired iron transport and failed sequestration: a novel mechanism for anaemia in systemic lupus erythematosus. , 2020, , .		0

#	Article	lF	CITATIONS
19	P065â€fThe road to recovery: developing a new service for urgent face-to-face rheumatology outpatient appointments during the COVID-19 pandemic: a single centre experience. Rheumatology, 2021, 60, .	0.9	o
20	A one-point increase in the Damage Index for Antiphospholipid Syndrome (DIAPS) predicts mortality in thrombotic antiphospholipid syndrome. Clinical and Experimental Rheumatology, 0, , .	0.4	0